• XELL Deutschland
  • XELL English
  • XELL China
Xell about us Slider

Our background

Here at Xell AG, we are distinguished by our skilled and motivated team of employees. They each have highly specialized scientific backgrounds, solidifying our strong focus on technology and innovation.

Emerging from the Institute of Cell Culture Technology at Bielefeld University, Germany, in 2009, Xell AG (formerly TeutoCell AG) has grown to become a strong biotech company dedicated to cutting-edge innovation and developing expertise. Since 2021 Xell AG is part of Sartorius.

With more than 20 years of hands-on experience in cell culture technology, Xell has drawn from its academic and technological knowledge to become a key partner in the design and distribution of cell culture solutions. We launched our first commercial products for CHO and hybridoma cell lines in 2010, and since then, Xell has continuously developed new tools for mammalian cell cultivation, benefiting from strong partnerships in industry and academia.

2015 saw Xell move to a new facility, and this gave us the additional capacity we needed to expand our portfolio of innovative off-the-shelf media. In 2019, a brand-new manufacturing facility was brought into operation, supporting large-scale production of liquid and dry powder formulations such as cell culture media, buffer and medical products. Today Xell has three main independent business divisions that work together closely:

  • Production of liquid and dry powder formulations – from cell culture media and feeds for CHO, HEK , BHK and hybridoma , to buffers and medical products
  • Analytics of spent media, food, feed and other sample types
  • Research and development – cell culture and process optimization services to enhance our customers’ knowledge and performance

Besides our ISO 9001 certification (Quality management system) obtained in 2019, we are working on our ISO 13485 certification (Medical devices — Quality management system) for 2022.

5 facts about Xell

Commercial references

As a medium-sized company, Xell is more agile and flexible than other international suppliers, yet we are still able to handle large-scale requests smoothly.

Years of experience have cemented Xell’s reputation as a reliable and dedicated partner for the science community and biotechnology sphere. From start-ups to universities to global players like Beigene, Sanofi and Boehringer Ingelheim, we are proud to serve all kinds of long-term clients.

Our partners

We collaborate with companies and universities around the globe to broaden our portfolio and create new and exciting initiatives to support your ideas.

ACYTE Biotech Pty Ltd is an Australian- based biotech company specializing in proprietary technologies in mammalian cell engineering and cell culture. ACYTE aims to reduce bottlenecks in early stage biopharmaceutical development by providing a suite of SuperCHO® technologies to streamline the path from discovery to clinic. Two key technologies include:

  • Epi-CHO, a high-yielding CHO cell based transient gene expression system
  • Stable cell line generation using a robust, well-characterized and high yielding expression system which meets regulatory expectations for clinical and commercial applications

ACYTE has a wealth of experience in stable cell line development combining its proprietary suspension adapted cell line, XL-99, with versatile, highly stringent expression vectors and high throughput clone selection platform. The system is ideal for generating cell lines in a rapid time frame which are scalable for clinical and commercial applications.

(Information provided by our partners)

Xell has partnered with ACYTE to combine fast stable cell line generation with highly efficient medium and feed solutions, tailored for the developed cells.

Visit ACYTE Biotech for more information on cell line development and contact details.

BIBITEC Gesellschaft für Prozessentwicklung mbH is specialized in the production and purification of proteins (e.g. hormones, mAbs) derived from mammalian cell cultures.One major achievement was an erythropoietin (EPO) project that involved the process development and the GMP- compliant production of an EPO biosimilar for use in phase III clinical trials.The entire production and purification process was successfully transferred for large-scale production leading to one of the first successful approvals of a biosimilar in Europe.

In 2012 BIBITEC became part of Nordmark Arzneimittel GmbH & Co. KG, Uetersen. In cooperation with Nordmark and other validated partners BIBITEC provides all activities from “gene to product” including cell line and process development, GMP production, fill-and-finish and analytics.

(Information provided by our partners)

Biofidus is a newly founded bioanalytical company located in Bielefeld, Germany. Its services include a wide variety of bioanalytical methods such as spectroscopic, chromatographic or mass spectrometric assays focused on characterization of proteins as well as small molecules.

The experts at Biofidus represent over 40 years of bioanalytical experience, allowing it to find the solution to your bioanalytical project.

Biofidus can help solve your toughest challenges from routine high throughput analysis to development of novel client- specific assays.

(Information provided by our partners)

InVivo is an ISO 9001 certified contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins for research, diagnostic and pre-clinical use. Since 1998 InVivo provides cost-effective outsourcing solutions for a large number of satisfied clients.

A wide range of different hybridomas have been cultivated in InVivo’s proprietary serum-free media ISF1. Production under serum-free conditions enables high productivity without the drawbacks of serum-containing processes, e.g. contamination with bovine IgGs. High cell density fermentation using different cell retention systems yields up to 500 mg antibody per liter per day. After a one step purification using recombinant protein- A/G our monoclonal antibodies are of highest purity.

Furthermore InVivo offers the complete range of modern recombinant protein expression techniques. Starting from synthetic cDNAs the protein can be expressed in bacteria, insect or mammalian cell lines. To meet customer ́s needs for mammalian derived proteins on short order we offer transient transfection using HEK- and CHO- cells. This fast and productive alternative is often favored over stable cell line development.

(Information provided by our partners)

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Their innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, Miltenyi’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture.

Their 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has more than 1,500 employees in 25 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.

(Information provided by our partners)

trenzyme GmbH is a privately owned German Contract Research Organization (CRO) offering a wide range of highly customized services in cell line development and recombinant protein production.

Since 2000, trenzyme has been a valued research partner of national and international clients, ranging from academia and small biotechs to big pharmaceutical companies. Their highly skilled scientific experts provide a one-stop-shop from cloning to development of stable assay cell lines or GMP-compliant production cell lines. Both cell line services rely on powerful and well-established platforms: their proprietary ExoIN technology (stable assay cell line generation) and the CHOvolutionTM platform (GMP-compliant production cell line development).

Whether your needs lie in the development of assay cell lines, production cell lines or in recombinant protein production, trenzyme’s team is continuously developing new and comprehensive solutions to provide reliable, up-to-date support for your individual and demanding projects. As full service provider for the life science industry, they are dedicated to delivering the ideal solution for their clients at highest quality standards and maximum efficiency, saving your valuable research time and accelerating your innovation.

(Information provided by our partners)

With our international network of partners in academia, we continuously work on innovative ideas to advance our industry.

By synergistic cooperation with these research teams, each experts in their field, we can transfer latest insights into practice.

Our research partners

  • AIBN, University of Queensland
  • Bielefeld University
  • Federal University of Rio de Janeiro
  • Fraunhofer Institute for Molecular Biology and Applied Ecology
  • Friedrich Schiller University Jena
  • Max Planck Institute for Plant Breeding Research
  • University of Kent
  • University of Lisbon
  • University of Oxford
  • and others


We partner with selected companies to distribute our products in different parts of the world.

RRR is located in Navi Mumbai, India and is engaged in business activities related to manufacturing and services in the field of fine chemicals, pharmaceuticals, biotechnology, surface coatings technology, industrial plants and equipment and platinum group metals. RRR works closely since many years with its partners, who are located mainly in Europe and the US.

(Information provided by our partners)

Visit RRR Labs for more information and contact details.